Literature DB >> 6640109

Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia.

K A Bauer, J B Ashenhurst, J Chediak, R D Rosenberg.   

Abstract

A family with a high incidence of spontaneous thromboembolism over four generations has been investigated. The propositus is a 21-yr-old male with a history of thrombophlebitis. Medical histories of 46 family members were obtained. Twelve of these individuals have experienced deep venous thromboses and/or pulmonary emboli. Seven members of the kindred, with a prior history of thrombotic phenomena, were investigated in detail. These subjects were found to have normal plasma concentrations of immunoreactive antithrombin (mean 96%), decreased plasma levels of progressive antithrombin activity (mean 50%), and greatly reduced amounts of plasma heparin cofactor activity (mean 42%). The abnormal antithrombin ("Chicago") was found to elute from heparin-Sepharose at a higher ionic strength than normal inhibitor. The functionally defective antithrombin molecules exhibit a reduced ability to neutralize thrombin in the presence or absence of heparin (approximately 10%-20% of normal). The molecular defect of this protease inhibitor thus appears to be distinct from those of previously described abnormal antithrombins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6640109

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.

Authors:  K A Bauer; L M Weiss; D Sparrow; P S Vokonas; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

2.  Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").

Authors:  J E Sambrano; L J Jacobson; E B Reeve; M J Manco-Johnson; W E Hathaway
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

3.  Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function.

Authors:  Yang Liu; Colin A Kretz; Morgan L Maeder; Catherine E Richter; Philip Tsao; Andy H Vo; Michael C Huarng; Thomas Rode; Zhilian Hu; Rohit Mehra; Steven T Olson; J Keith Joung; Jordan A Shavit
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

4.  Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.

Authors:  E M Conway; K A Bauer; S Barzegar; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

5.  Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency.

Authors:  K A Bauer; T L Goodman; B L Kass; R D Rosenberg
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

6.  Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium.

Authors:  J A Marcum; J B McKenney; R D Rosenberg
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

7.  Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity.

Authors:  D Stern; P Nawroth; J Marcum; D Handley; W Kisiel; R Rosenberg; K Stern
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

Review 8.  Fishing for answers to hemostatic and thrombotic disease: Genome editing in zebrafish.

Authors:  Azhwar Raghunath; Allison C Ferguson; Jordan A Shavit
Journal:  Res Pract Thromb Haemost       Date:  2022-08-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.